Eton Pharmaceuticals vs Zevra Therapeutics
Zevra Therapeutics is the larger business, with $106m of revenue in fiscal 2025 against $80.0m for Eton Pharmaceuticals (1.3 times as much). Zevra Therapeutics grew faster (350.9% against 104.9%). Zevra Therapeutics kept more of each dollar of sales as profit: a net margin of 78.2% against -5.8%. Zevra Therapeutics carries less debt relative to equity (41.1% against 116.8%).
| Latest fiscal year | Eton PharmaceuticalsETON, 2025 | Zevra TherapeuticsZVRA, 2025 |
|---|---|---|
| Revenue | $80.0m | $106m |
| Revenue growth | 104.9% | 350.9% |
| Net income | −$4.6m | $83.2m |
| Operating margin | -1.1% | -59.1% |
| Net margin | -5.8% | 78.2% |
| Return on equity | -18.2% | 85.7% |
| Free cash flow | $10.2m | −$2.4m |
| Cash | $25.9m | $62.4m |
| Total debt | $30.6m | $63.6m |
| Debt to equity | 116.8% | 41.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 44 | 61 |
| Market value | $1.44bn | $604m |
| Price vs our value range | Above our value range | — |
| Moat score | 35 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 29 sales | 0 buys, 13 sales |